Literature DB >> 20653496

Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient.

Eynat Kedem1, Eduardo Shahar, Gamal Hassoun, Shimon Pollack.   

Abstract

INTRODUCTION: Iatrogenic Cushing's syndrome (CS) is caused by exposure to glucocorticoids and may be promoted by interaction with additional drugs. It is well known in asthmatic human immunodeficiency virus (HIV)-infected patients treated with inhaled fluticasone with ritonavir-containing antiretroviral regimen (cART). CASE REPORT: The authors present an asthmatic HIV-infected Ethiopian woman, treated with fluticasone/salmeterol, commencing cART with tenofovir, emtricitabine, and lopinavir/ritonavir. During 7 months she gained 9 kg and hyperpigmentation, mild edema, marked abdominal striae, and increase in blood pressure were noted. Plasma am and urine free cortisol levels confirmed CS diagnosis and fluticasone was discontinued. Complete resolution of CS occurred within 2 months. However, frequent asthma symptoms required resumption of inhaled corticosteroid (ICS) treatment, and budesonide/formeterol was prescribed. Soon reemergence of symptomatic CS was noted. Ritonavir dose was halved, but CS symptoms continued to develop. Budesonide was stopped and montelukast initiated. Resolution of cushingoid symptoms was observed within weeks. DISCUSSION: Corticosteroids are metabolized by cytochrome P450 3A4 (CYP3A4). Fluticasone has the longest glucocorticoid receptor-binding half-life and is 300 times more lipophilic than budesonide. Inhaled fluticasone possesses a high suppression rate of hypothalamic-pituitary-adrenal axis. Ritonavir, a potent CYP3A4 inhibitor, may inhibit corticosteroid degradation and increase its accumulation. Inhaled budesonide is less likely to cause adrenal suppression. Diagnosing Cushing's syndrome presents a clinical challenge due to similarities with clinical manifestations and side effects related to cART. In patients treated with inhaled or intranasal corticosteroids together with cART there may be a higher incidence of iatrogenic CS. CS should be looked for, and management considered carefully.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653496     DOI: 10.3109/02770903.2010.485666

Source DB:  PubMed          Journal:  J Asthma        ISSN: 0277-0903            Impact factor:   2.515


  25 in total

1.  Cushing syndrome due to ritonavir-fluticasone interaction.

Authors:  Eduardo Canalejo; María S Pacheco
Journal:  CMAJ       Date:  2012-05-14       Impact factor: 8.262

2.  Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone.

Authors:  Navnit Makaram; Clark D Russell; Simon Benedict Roberts; Jarrad Stevens; Gavin Macpherson
Journal:  BMJ Case Rep       Date:  2018-12-14

3.  Linear growth arrest without weight gain due to overuse of topical clobetasol.

Authors:  Zahra Razavi; Milad Sanginabadi
Journal:  Oman Med J       Date:  2014-11

4.  Iatrogenic Cushing Syndrome from Interaction Between Ritonavir and Oral Budesonide During Direct Acting Antiviral Hepatitis C Therapy.

Authors:  Sern Wei Yeoh
Journal:  J Clin Exp Hepatol       Date:  2016-05-20

5.  Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide.

Authors:  Olivier Veilleux; Todd C Lee; Emily G McDonald
Journal:  CMAJ       Date:  2017-09-18       Impact factor: 8.262

6.  Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

Authors:  Alice Tseng; Michelle Foisy
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

7.  Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies.

Authors:  Emilie R Elliot; Aikaterini Theodoraki; Lakshmi R Jain; Neal J Marshall; Marta Boffito; Stephanie E Baldeweg; Laura J Waters
Journal:  Clin Med (Lond)       Date:  2016-10       Impact factor: 2.659

Review 8.  Disease drivers of aging.

Authors:  Richard J Hodes; Felipe Sierra; Steven N Austad; Elissa Epel; Gretchen N Neigh; Kristine M Erlandson; Marissa J Schafer; Nathan K LeBrasseur; Christopher Wiley; Judith Campisi; Mary E Sehl; Rosario Scalia; Satoru Eguchi; Balakuntalam S Kasinath; Jeffrey B Halter; Harvey Jay Cohen; Wendy Demark-Wahnefried; Tim A Ahles; Nir Barzilai; Arti Hurria; Peter W Hunt
Journal:  Ann N Y Acad Sci       Date:  2016-12       Impact factor: 5.691

Review 9.  Human immunodeficiency virus-associated obstructive lung diseases.

Authors:  Matthew R Gingo; Alison Morris; Kristina Crothers
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

Review 10.  Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management.

Authors:  P Saberi; T Phengrasamy; D P Nguyen
Journal:  HIV Med       Date:  2013-04-16       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.